Primobolan (Methenolone) Steroid Profile

Primobolan is the trade name for the anabolic steroid Methenolone. It is obtainable to administer through the oral route or parenteral route.

Injectable Primobolan is known as Primobolan Depot/Methenolone Enanthate, and the oral administered drug is known as Methenolone Acetate. It is a very well-known and popular anabolic steroid due to its very mild nature as both an anabolic and an androgenic compound.

Primobolan is carefully considered one of the most capable anabolic steroids and it typically carries an excellent safety standing. This steroid can be used successfully to treat underweight children and premature babies as well without harm. It’s also prescribed for osteoporosis and sarcopenia.

Until now, the primary purpose of Primobolan is to treat muscle-debilitating conditions and prolonged exposure to corticoid hormones. It has also proven to be extremely effective in combating malnutrition.

Primobolan properties and specific details were first released and published in 1960. Squibb released the injectable format of Primobolan (Methenolone Enanthate) first in 1962 followed by the official release of the oral variant of Primo (Methenolone Acetate) into the American market in the same year.

It was at that considerable time marketed under the brand name Nibal Depot (for the injectable) and Nibal for the oral variant dosed at 20mg per tablet. 

Remarkably afterward, the rights to manufacture the compound were sold in West Germany to Schering. Following this sale of rights, Nibal was removed from the US market, and instead, Schering marketed the compound under the new trade name Primobolan (for both variants).

It subsequently became the quintessential anabolic steroid manufactured by Schering, who then marketed the compound as an internationally exclusive drug, and would never return to the American Market.